Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CTEPH: Dual Oral Therapy vs Monotherapy in Inoperable CTEPH
NCT04780932Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2021; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT04780932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780932.